<SEC-DOCUMENT>0001571049-15-002269.txt : 20150324
<SEC-HEADER>0001571049-15-002269.hdr.sgml : 20150324
<ACCEPTANCE-DATETIME>20150324161703
ACCESSION NUMBER:		0001571049-15-002269
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150324
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150324
DATE AS OF CHANGE:		20150324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		15721926

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1500686_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of Report (Date of earliest event reported):
March 24, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of registrant as specified in
its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of incorporation)</B></P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>200 Connell Drive, Suite 1500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Berkeley Heights, NJ 07922</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices and
zip code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registrant&rsquo;s telephone number, including
area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 80%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction
A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 2.02 Results of Operations and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The information set forth under this &ldquo;Item
2.02. Results of Operations and Financial Condition,&rdquo; including the exhibit attached hereto, shall not be deemed &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference
into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attached as Exhibit 99.1 is a copy of a press
release of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;), dated March 24, 2015, announcing certain financial
results for the fourth quarter and fiscal year ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company will conduct a conference call to
review its financial results on March 24, 2015, at 4:30 p.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 8pt">
    <TD STYLE="vertical-align: top; width: 9%; font-size: 8pt"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 8pt"><B>Exhibit</B></FONT></P>
        <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 8pt"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 2%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 89%; font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Press release announcing financial results for the fourth quarter and fiscal year ended December 31, 2014, dated March 24, 2015.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%; font-size: 10pt"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 24, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1500686_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 50%; font-size: 10pt"><IMG SRC="logo.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cyclacel
    Pharmaceuticals, Inc.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS REPORTS FOURTH
QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&mdash; Conference Call Scheduled
March 24, 2015 at 4:30 p.m. EDT &mdash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Berkeley Heights, NJ, March 24, 2015
</B>- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;), a biopharmaceutical
company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
disorders, today reported its financial results and business highlights for the fourth quarter and full year ended December 31,
2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company&rsquo;s
net loss applicable to common shareholders for the fourth quarter ended December 31, 2014 was $4.8 million, or $0.21 per basic
and diluted share, compared to net loss applicable to common shareholders of $3.6 million, or $0.20 per basic and diluted share
for the fourth quarter ended December 31, 2013. As of December 31, 2014, cash and cash equivalents totaled $24.2 million. Following
the Company&rsquo;s public offering of common stock in March, 2015, proforma cash and cash equivalents is approximately $34.6
million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;2014 was a defining year for Cyclacel
as we completed enrollment of our SEAMLESS study, one of the largest Phase 3 trials as front-line treatment of elderly patients
with acute myeloid leukemia (AML), and also completed Investigational New Drug (IND) -directed development of CYC065, a cyclin
dependent kinase (CDK) inhibitor, the area of research Cyclacel was founded to pursue,&rdquo; said Spiro Rombotis, President and
Chief Executive Officer of Cyclacel. &ldquo;Although the SEAMLESS independent Data Safety Monitoring Board (DSMB) determined in
an interim analysis of approximately half of the required events that the futility boundary had been crossed, they saw no reason
for the trial to be discontinued and recommended recruited patients should stay on study. We will follow-up patients until the
prespecified number of events has been observed, which we expect to occur between the second half of 2015 and the first half of
2016. Subject to the outcome of SEAMLESS, we are preparing for potential regulatory submissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CYC065, our novel, second generation CDK2/9
inhibitor, has demonstrated therapeutic potential to treat acute leukemias and in particular those with rearrangements in the
mixed lineage leukemia (MLL) gene, as well as solid tumors, including certain subtypes of breast cancer. We believe that the pharmaceutical
industry has increased interest in CDK inhibitors following the recent first-in-class approval of palbociclib for metastatic breast
cancer. CYC065 targets with greater potency and improved properties the same CDK enzymes as our first generation CDK inhibitor,
seliciclib, which demonstrated signals of anticancer activity. We expect to file an IND application for CYC065 during the first
half of 2015 and begin Phase 1 trials shortly thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Including net proceeds from a recent financing,
we have sufficient cash resources to pursue both our sapacitabine and CYC065 programs for at least the next two years.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Sapacitabine</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Completed
                                         enrollment in the SEAMLESS, pivotal, Phase 3 study for front-line treatment in patients
                                         aged 70 years or older with AML, in approximately 110 U.S. and European sites, one of
                                         the largest studies in this patient population.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="font: 8pt Wingdings">&thorn;</FONT><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey 07922, USA Tel +1 (908) 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="font: 8pt Wingdings">&uml;</FONT><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><U>www.cyclacel.com
</U>&ndash; <U>info@cyclacel.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         SEAMLESS Data Safety Monitoring Board (DSMB) conducted the final planned safety review
                                         of 470 randomized patients with at least 60 days of follow-up and found no safety concerns.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         DSMB determined that the futility boundary had been crossed after 247 events and determined
                                         that it would be unlikely for the study to reach statistically significant improvement
                                         in survival; however, the DSMB saw no reasons why patients should discontinue treatment
                                         on their assigned arm and recommended that recruited patients stay on treatment.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
                                         </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         28% of the prespecified events remain to be observed until mature data becomes available
                                         for analysis.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Completed
                                         enrollment of patients in an additional part of the ongoing MDS Phase 2 study evaluating
                                         better dosing regimens.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Disclosed
                                         proposed myelodysplastic syndromes (MDS) study design for a Phase 2b randomized controlled
                                         trial (RCT) in patients aged 60 years or older with intermediate-2 or high-risk MDS who
                                         have failed prior hypomethylating agent therapy.</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conducted
                                         feasibility study and determined that the proposed MDS Phase 2b RCT design is feasible.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>CYC065
(2<SUP>nd</SUP> generation CDK inhibitor)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Completed
                                         IND-directed development. Preparation for IND submission to the U.S. Food and Drug Administration
                                         (FDA).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Presented
                                         preclinical data at the 2014 Society of Hematologic Oncology (SOHO) meeting demonstrating
                                         therapeutic potential of CYC065 to treat acute leukemias, and in particular AML and acute
                                         lymphocytic leukemia (ALL) with rearrangements in the MLL gene. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Appointed
                                         Samuel L. Barker, Ph.D., to the Board of Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cyclacel&rsquo;s Key Milestones for
2015-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Sapacitabine</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continue
                                         to follow-up enrolled patients in SEAMLESS until the prespecified number of events is
                                         observed, which is expected to occur between the second half of 2015 and the first half
                                         of 2016.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Submit
                                         a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMA).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continue
                                         follow-up of patients in an additional part of the ongoing Phase 2 MDS study evaluating
                                         better dosing regimens.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Make
                                         a decision on Phase 2b RCT in MDS following review of all relevant clinical data with
                                         mature follow-up. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Report
                                         updated data from the Phase 1 study of sapacitabine in combination with seliciclib in
                                         solid tumor patients, in particular those carrying gBRCA mutations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>CYC065
(2<SUP>nd</SUP> generation CDK inhibitor)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Submit
                                         IND to the FDA during the first half of 2015.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Multiple
                                         presentations at the American Association for Cancer Research (AACR) 2015 annual meeting.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiate
                                         a Phase 1 clinical trial in patients with advanced solid tumors, subject to IND acceptance.
                                         </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Seliciclib
(1<SUP>st</SUP> generation CDK inhibitor)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Support
                                         academic collaborators in investigator sponsored trials (IST) of seliciclib in patients
                                         with Cushing&rsquo;s disease and rheumatoid arthritis who have failed prior treatments.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Fourth Quarter
2014 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Grant Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue for the three months ended December
31, 2014 was $0.2 million compared to $0.3 million for the same period of the previous year. The revenue is related to previously
awarded grants from the UK government being recognized over the period to progress CYC065, a CDK inhibitor, to IND and to complete
IND-directed preclinical development of CYC140, a novel, orally available, Polo-Like Kinase 1 (PLK 1) inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
to $4.4 million for the three months ended December 31, 2014 compared to $2.5 million for the same period in the previous year.
The increase was primarily due to increased study and product costs associated with the expansion of the SEAMLESS Phase 3 trial
into Europe as well as increased expenditures related to grant funded research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses for
the three months ended December 31, 2014 decreased to $1.6 million compared to $1.8 million for the same period in 2013. The decrease
was primarily due to lower legal and professional fees during the three months ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on current plans the Company estimates
that it has capital resources to reach beyond the final analysis of SEAMLESS and continue existing programs through 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conference call and Webcast Information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cyclacel will conduct a conference call
on March 24, 2015 at 4:30&nbsp;p.m. EDT to review the fourth quarter and full year 2014 results. Conference call and webcast details
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conference call information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">US/Canada call: (877) 493-9121/ international
call: (973) 582-2750</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">US/Canada archive: (800) 585-8367 / international
archive: (404) 537-3406</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Code for live and archived conference
call is 8143261</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the live and archived webcast, please
visit the Corporate Presentations and Events page on the Cyclacel website at <U>www.cyclacel.com</U>. The webcast will be archived
for 90 days and the audio replay for 7 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Cyclacel is a
biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of
cancer and other serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase
3 trial, which has completed enrollment and is being conducted</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">under an SPA
with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other indications including myelodysplastic
syndromes (MDS). Cyclacel's pipeline includes an oral regimen of seliciclib in combination with sapacitabine in a Phase 1 study
of patients with Homologous Recombination (HR) repair-deficient breast, ovarian and pancreatic cancers, including gBRCA positive
tumors, and CYC065, a novel CDK 2/9 inhibitor, with potential utility in both hematological malignancies and solid tumors. Cyclacel's
strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline
of novel drug candidates. Please visit <U>www.cyclacel.com</U> for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that
include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot;
&quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot;
&quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot; or the negative of those
words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties
the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with
the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information,
future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts for Cyclacel Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company: Paul McBarron, (908) 517-7330,
<U>pmcbarron@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations: Russo Partners LLC,
Robert Flamm, (212) 845-4226, <U>robert.flamm@russopartnersllc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&copy;
Copyright 2015 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CYCLACEL PHARMACEUTICALS, INC.<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In $000s, except share and per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Three
    Months Ended </FONT><BR><FONT STYLE="font-size: 8pt">December 31,</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Years
    Ended </FONT><BR><FONT STYLE="font-size: 8pt">December 31,</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2013</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2013</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">(Unaudited)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">(Unaudited)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Grant revenue</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">299</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">247</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">1,084</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">1,734</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">247</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,734</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,491</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,277</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,277</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,782</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,613</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,781</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,894</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total operating
    expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,273</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,029</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,058</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,171</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Operating loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,782</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(17,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(22,437</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in valuation of financial instruments associated with stock purchase
    agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(98</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(227</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(98</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(342</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in valuation of Economic Rights</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">570</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in valuation of liabilities measured at fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Foreign exchange gains</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">88</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,547</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">114</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(52</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(125</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,094</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(212</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Loss from continuing operations
    before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,026</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,907</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,880</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,649</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Income tax benefit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">452</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,108</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,670</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,243</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,574</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,799</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,210</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,406</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Discontinued operations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Income from discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Income tax on discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(34</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net income
    from discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">57</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,559</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,799</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,153</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,387</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Deemed dividend on convertible exchangeable preferred
    shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,027</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Dividend on convertible exchangeable
    preferred shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(298</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss
    applicable to common shareholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,609</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,849</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(19,478</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(19,587</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss per share, continuing
    operations &mdash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.20</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.21</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.29</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.89</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Net (loss) income per share,
    discontinued operations &mdash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss per share &mdash; basic
    and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.20</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.21</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.28</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.89</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Weighted average common shares outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,788,568</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,986,528</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,158,225</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,955,381</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CYCLACEL PHARMACEUTICALS, INC.<BR>
CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In $000s, except share, per share,
and liquidation preference amounts)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">December&nbsp;31,</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2013</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(Unaudited)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">31,146</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">24,189</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,388</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,640</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Current assets of discontinued
    operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">639</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">171</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Property, plant and equipment (net)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">387</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Long-term assets of discontinued
    operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">72</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.35in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,520</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,387</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">LIABILITIES AND STOCKHOLDERS&rsquo;
    EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,792</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accrued and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,626</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Other liabilities measured at fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Current liabilities of discontinued
    operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">260</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 34.2pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,256</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,493</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Other liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">241</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">206</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 34.2pt">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,497</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,699</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Preferred stock, $0.001 par value; 5,000,000 shares
    authorized at December&nbsp;31, 2013 and&nbsp;2014; 335,273 shares issued and outstanding at December&nbsp;31, 2013 and 2014.&nbsp;Aggregate
    preference in liquidation of $3,989,749 at December&nbsp;31, 2013 and 2014.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Common stock, $0.001 par value; 100,000,000 shares
    authorized at December&nbsp;31, 2013&nbsp;and&nbsp;2014; 19,369,332&nbsp;and 23,199,469 shares issued and outstanding at December&nbsp;31,&nbsp;2013
    and 2014, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">317,543</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">330,962</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Accumulated other comprehensive income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(109</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(480</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Deficit accumulated during the
    development stage</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(289,430</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(308,817</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 34.2pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28,023</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,688</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 34.2pt">Total liabilities and stockholders&rsquo;
    equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,520</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,387</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SOURCE: Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X00O:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C8M8S`Q-"`W.2XQ-38W.3<L(#(P,30O,#@O,C`M
M,#DZ-3,Z,#(@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z0D0P039"-4)$,C4X,3%%-$%%.49#-3A$,C<R
M,D4S,S`B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z0D0P039"-4%$,C4X
M,3%%-$%%.49#-3A$,C<R,D4S,S`B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#ID,C1C9#1D-2UE-&1A+30W,V4M8C8Y,RTU
M-S!F,V4S,&9E8C4B('-T4F5F.F1O8W5M96YT240](G5U:60Z9#@P93<R.3@M
M,S0S-2TT-F0W+6(R,3$M83`S9F%F,F,Y9#9C(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YG:6QA;'9A<F5Z/"]R9&8Z;&D^(#PO<F1F.E-E
M<3X@/"]D8SIC<F5A=&]R/B`\9&,Z=&ET;&4^(#QR9&8Z06QT/B`\<F1F.FQI
M('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@0UE#0R!0
M4B`T43$T($9I;F%N8VEA;"!297-U;'1S($9)3D%,+F1O8W@\+W)D9CIL:3X@
M/"]R9&8Z06QT/B`\+V1C.G1I=&QE/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R
M9&8Z4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0
M:&]T;W-H;W`@,RXP`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X0DE-
M!"4``````!#\X1^)R+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;`(0`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("
M`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`
M1`"U`P$1``(1`0,1`?_$`*H``0`"`P$!`0$````````````("08'"@4$`P(!
M`0`!!0$!`0`````````````&`P0%!P@""0$0```&`@$#!`$#`@,%"0````$"
M`P0%!@<(`!$2"2$3%!46(A<8,0I!,B-B)"5WMS,F)S='*#@9.1$``0,#`P,"
M!`0#!@8#`````0(#!``1!1(&!R$Q$T$442(5"&$R(Q9"4A=Q@6(D)1BA<C-3
M-$1C<S7_V@`,`P$``A$#$0`_`._CBE:JS+FW%^O]&DLBY;MT93ZM&@"?RGQS
M'=R3XY3&;Q,)&H%5?S,N[$@@DW;IJ*&Z"80`I3&"1;7VIN#>>7;P>VXSDK(N
M>B>R4^JW%&R4('JI1`].Y`J);UWSM7CS`N[EWA,:A8EKIJ4;J6KT;:0+K<<5
M_"A`)/4]`"1SIY_\UV:<BSBM+U/H@TR/=KJ-8NQ3,(6ZY,G0`QBD7BJLW3?0
M<+[Q/7VCI22Q?Z]Q!Z@';^S?M3VK@X@RO(TSW3Z0"MM#G@BM_@MXE+CEOB"T
MD_`U\V>0_OCWQN6><'Q%C_8QUJ*6WG&O<S7?Q;8`6TU<?PE+RA\0>E1N=X!\
MMVQQ!?VF&S_+LGZ8N2IWZX-:%%"0!,AT3@)F:KZ#(>PP@!?B)]Q/7U#UY.6]
MY?;9L<^''NX9IU!M>.R9"_CU<0APJ_MUGK^-:S>X\^\'DM/N,LSN%YAP:K2Y
M*8C=NW1IQUD)_L\8N.O:L5<Z+^37$3@9Z#H&66KU!)8WV.-,C1]@DDTTB")P
M3+5+6ZD5#'*8>PB1#G/_`$*`CS(M\N\![E1[.7,QJFB1\LJ,IM))_P#N9"1^
M))`'K6)<X%^Z39SOU"!C\PA](/SPIB'E@#O;V[ZEF_H`"3Z"LBQOY0=\-;;&
M6LY(EI6[(1JH)25#SG6WC*P)I(@#<Z;>=%I#VUFHF"?0IU3ND>\.IB']>MCG
M?M^X?WU!]_@FVXBW!=,B`ZE39)ZW+=ULJ'Q`"#;L162VS]U7/_&63&+W,\[.
M;:-EQ,HRI+P`Z$!W2W(2>G0J+B;]2DUT&:;^27!>WB:%;9KJ8YRZ1L*SS&EH
M>-Q<20)%`7+JFS12H,[2S2`>XR9"I/4B]3';@0.\>+N4."MW\:*,YT"=MHJL
MF4TDV3?L'V^JFE'L"26R>@62;5]%.%?N;V#S&E.,94<;O$)NJ$^H77;NJ,[T
M2^D=R`$NI%RIL`:JL.YI.NCZ<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*U9FK,5'P%C"W9:R+)?6U2G1AY!Z*0%4?2#@QBH1\/$MC'3^9+R[Y5-NV
M2`0[E5`ZB!0$P2':NV,MO+<$;;>#;\F1E.!*;]$I'=2UG^%"$@J4?0#U-A43
MWQO3`\>[5F;OW([XL3":*U6L5+5V0VV"1J<<60A"?51%R!<CF"K&/=BO+MF.
MP9AR78AQ=KC0GCU!2:>+@6L46O,RB]<UNFM7JJ,=+6\8SM6EI5<00;]W>L;L
M!%L/?\_-['^VG;#.V,"Q]0WS,2D^-(_5D.*^4.OE(*D,Z[I993\RNR1<J77R
MOQ>W.2?O&WI(WGNB3]*XSQZU`NJ/Z$5E/S*9C)40AR1HLJ1(7\J.ZS8(:K9;
M;:.K8TGU];_$GKXE;;:4BT?/9_?UPUSN5D41Z-W<O%.9))--*"`R8C]C*JMX
MKU$4&92=IS8%?'V0ST(;Y^Y+-&-C;A3>.2[X&&K]0A8222Y_\3(4]_.Z3<"3
MM\K8G:^15QI]G^W!,S`!0[EEL^YDO$=%.-J6``UT)\SZD,?R,A-E'4N4M>-D
MIA5R^W3\A.,L73KE-4Z]"MN8)^Y61E^KY0M%Z#0S(PT8B7WA$B2`'`!ZE(3H
M'I)-O;VV+%2EGBK94_(1$D6D,PFV&E>FH2)%UK/3J56^)-1#=?&_)LU:G^<.
M1L7BIZ@28DC(NR7T_P`6DQ(MFVQUZ)1?X)3TK3U?UE2;NBN,!>1[!<K<`/VM
MHD^0LBX3EI%=(GR$&\9*V))O'NU3F)T`%ED4@-Z=PCZ<D\W?REM^/>6QLPWC
M+=5^VC3D)!Z$J0T2I(_Y0HV]/6H9CN+D-NASCSDO`NYF_1LS)F,<61U`0X\$
MH4>G34I*;]+WZ5GUYS_M'AQ2.Q-Y#<*I;!XQDRF3BGF26K!Q:P9*BF96<Q%L
M!7`7,\?D2Z*$$[MWW`/0_M`81##8C9G'VZ$KW)PGE3A<^WU6F*5!G4+V;FXY
MVVE-^ALA'X:K5(,]R'RMLI36T?N.P:=Q[6=N&U34H,C2;7=Q^79OJ6!U%W'+
M]CIO>OOI_C>G,WRU/S5HKE>.E</.[(W<'FK]-&J64<"6"'=-7KV*M3=@V-]Q
M(UU!5-=N[8"0SI/M-V]ABK'H97G6'M"+*VMS!CEM;E1'(T1T>:)D&EI4D+:*
MC^FAP@I4ARX0;B]P4BZP?VRY#?TV%O;@'+MO;/<E)(<E.%B?BGFU)4IM]*$_
MJ+9!"D+:L7!8VL0M5I6B_GG\?6_&SMSTZP->;[+96I$7./(6=MM(4KM/S`PI
M?LM[;,XZEB23]RY)'B)G/M23:,7<-"G7;D53(<Q?FJZI*W5+0G2@J)`^`)Z#
M^[M7V(80MME#;JM;B4@%7;40+$_WGK5U//%5:<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2N?#R5S-QW`V^POX_L<R*[.#A5F%URE(MA%1M'/7[(\@K)R
M*13BDL6E48QG#=,_3W'TH0@AU[!YVGP1%Q?&7&>5YGSB`J6Z%,1$GH5)2K2$
M)/<>=^R5$=FVB>UZ^='W/3<WS-S)@_MXVTZI$!A2),Y8ZA"EIUE:Q>Q]M%NM
M`-M3KZ4][&OMVHC)?(]\QCXEM/BEI&/JK78R7V`LT:`*MX2KE^+("PGW")T5
M)!94CI.1D4S*E4E91\V0.(![W*/'DB-@\/D/N0Y-_P`WFI+ZT8YI70N.]4ZF
MP;A(%BTT0"&6FW%BYTU<<L1)FY<_BOM`X8`@;=B1D.9=]'4-,?*O0ZH$%9.I
M+SP*@9#[K3:B!KK7T6TE9]M<]7?']+Q&`-9<2>\TV?W9G'*;.7N$[&-!)8$F
M-N`[)T[%$I#%`&:[<H@(^VHT9"3W\W(<CPW(O(/,[;N9W]DK*Q6";&I#+:U?
MIE3/S`7Z?G2K_$EUV^B.169>0:F\4_;P\SMWB[#W3G-S.J"7)#J$V="9%TJ5
M:QMXU(!'Y5,L%/DTQ0\,ZRR7V2.M&E6>-^)%HN9*5SME"TS&-\73,XDX.FZ=
M01431",PQ<*'$QBN/]?M`#"*@=QAE.8W3OUCQJWYNO#[.84FZ,?$91*EH;(Z
M!R^LH4!TNGY?3Y>@J%8#8_%TGRM\9;'S_($I"B',I.?<A07'0HA2F@/&'$DW
M)#EEV`/S"Y/G92Q/C*O1;I_LKXM<IX#JBBY`>99UVR/)6MM6&H)BF9[)0,@,
MO3C()*JE/VKF:`IV&Z"80$.5MO;CS\V0EG8G(6.S.1`^6'DHR62Z;WTI<3H?
MN0"+I"[7':K;=FT-JXZ*N1R=Q3EMO8@J^;(8>8M\,"UM2VE^2-8$@V66[V-B
M36;Z[86R"Q/7H2A9$I6W/C1R`[77RM^XDLR@&.#X.,:*R-CG+1"6&69S.)+Y
M2HI,SM)[%JD:N@*!C%(4Q#%P?(&\]N,1967W)%D;5YNQK)5'6R"H3#V2$/(2
M6I45T_*M+XU-B_4V(J2\5<=[NDS8.`V?-B[X^V_,/A$MJ00DX\=UJ<CN+#T&
M:RDZFU1CI=-OE&I)&NLN;&[>8!RQHU1?!+@3%NW'C]S7=GBNP>;:<\/F^%EK
MX:]IU:_5B^95B+0M'XFC:;CN);N&\D]*1$ZJPI`"OQQ06XTWMOO<O(67&;W0
M^'IJ6DMITI2A"$))(2E"0``5*4H^I)))KZ&<<<8[.XHP!VYLJ,8^.6^IY94M
M3CCCB@`5K6LE1(2E*4CH`E(`%68:4^!CQX:";37K;S7NBW6.RE;VMGC8)A9;
ML[GZ;B^*N:Z:]FCL=01V;5=@E(D(+<JD@YD5VS,YT$#IIG.!H?4_JYGBE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5BY;O33-U'9;77#-$2HG6=%FHX6R2
M;D7!6ZJC@'/M$1<':*E(<1`AS)G*`B)1`%*I7\9R+#(V?]\]SIT2.47]^EZ9
M5)90ABMV]6C55Y^5,U6746%`OTL?#$,`#^@J8A_E'H'77/2GL'LS9W%L.Z5H
MAH?>0.Y=4`VBX`%_U%/D?$GXBN"OM?1'W+R'R!S;/LM#F0<C1W".@805.N:2
M2;?I(C`V[`6[&PTAB20NE;TCSYL_#%6-L1Y`L[+8WH<R<2`_B8V]7A[2*^BS
M==A%FJ#%%65=)&1ZE_0V,``"9>V6;D9Q4[EC#;`E$#9.R\.)4A'\*U1V$ON%
M0[$J(90=77JX/4W@VSY.:QG!FX.5(04>1N1,^845P]%MHE251FDI5:Z0F\A:
M2GIT:/9(MN*^8IQQ5(MOK(JSDW.IFE5)IMNS96JX(-IS9?8^_J(.<?XSD%6I
MR+R03+YR@^=MQ,'N.9-HW-VID3,G&,/N+.Y&0K?R5-IY(W7+?9@.N]6\7C(X
M(D2D@]$Z$A3:%6Z):<6+J*@J:9_:>V<1%3Q<M#J^(]CP8TC)LL_*[FLS+(5$
MA+TV*_*M275HOU6\RV;)2A29<U72.5R]"1DYMO:[`Y!5HW&!ULQ1:9;'>!<1
MPW=[C"H-HZE.85Y>Y6-:=B#R1>K"@LH4X((E2!,>:UR'+$;;,MR)QM'9391\
MF4F,HDY"8OLIXJ?#B8Z%&ZD-(3J2+%:BHD5N#$\%R]Y06IW+\N2H*0GQ86`^
MY#Q6/;[HCI1&+2I3B$V2X\XK2HZ@A`0$FO,MGCSJ6,&;JYZI9?NNLEJCSBX5
M92EOFKMA&?9JK)?)A+WC^Z2LA'.89Z``GW(K(G3$W7H<W3I[A\XS<Q:!R9CX
M6<Q*A;6&FXTUH@&SC$IE*"E:3U^8$'M<"O$_[:L;M_\`U+AS*Y';>;2J_B+[
MLO'/I)&IJ3#D+<2IM0%OE(*;WLHUK""PQ8\IW5YC_7.@8ZPMJPVR_GG#?DJQ
MCEO`%\I$GM,E*8M@X1G-ZV2Z[XC,,8.WME=$2E&:J#%P0RA6ZAQ;K)*ZMW-N
MW/;K?95FIDF6S%;+4?SK"UML@DI256&I7;4L]5$=3VMNO9NQ-K['C/HV[`AP
M7YKH>E>W06VW'RD!2TH*E:$7OH;39*0387))FMI?I)K;X_<'Q^N^JU"4QYBU
MA8I^V#$N;#8K7)/[)9ED59>8E)^TR<O,R#M=)H@@7W%A*FW;I)E`"D#D9J95
M+#BE5$;+>:[3O7O-,UK/48?/.WFRE73*:Y8.TQQ!-9XN-$546;-TF=\D(IS&
M4^HR/NN2E4;/)--RU'T<)I")>Y2L2D?-SARM:\9ZV)R'J%Y!,4Q6L;O'YLV8
M\RAK<%*R/6:SD.5F89E?(1C+W)&LWFF5Q_#&":=0TJ]/%I*IK+)@B(G*I5K^
M.\M8ZRMBJGYNH=MAI_%E\I$/D:L75L]0+!R%,G(=&>83AGJAR(MFGU:X**BH
M)?9Z&`_:)3`"E0JUD\H^K>T6O&9-NH"3LF,-6,-W2[5)SGW-3.#H..KY&X_=
M?`L60L?RBMAD%Y;'OV8@S:OG*3-5V]`[9-`5TSI@I4,F/]P1KM>"O;'@#3CR
M8[/X=CC+*.L_8+TWM<YB9U'(/EX\\Q7I&SS=2L=JC?D("`#'QCA3IZB0.*5-
M&S^3K7NIY*T`Q9*5_+J-E\D$;8I3!!'E%+!C7D*S38:[R3;+,78I>(L-'E21
M<XBD+/X3IRD[*HDJ1,2&'BE6+<4JL;R7>6?5GQ55;%MFV20R3.+9?GK+#T^K
MXGK$9;K6HPI<*E/W*UOHJ2L5<*WJU6CG2`O')5%!2,X3_1V]QBJ58?1+M6<E
MTBG9&I4JWG:;?JM7[I4YMH;N:S%:M,2TG(*4;F_Q0?Q;Y)4G^R<.*56KMMYC
M-.]2<NH:XNQS!L3LZK$#.N-<-3<46+.V682).D@LV>VR+KGL0E/([1=)*$3D
MG[9Q\=0BXI@B<BAE*]/7+RG8_P`_.,P0]BU;W>UDMV%,4SF9;55-H=>WN,7$
MM2J\DV5D%:984+!/TVT2Q?F)@#1"2!8.[J8"E*82J5!S&_\`<>8'S)28C).(
M?'WY7\I8]L!7IH&[X_T\_+*I-_6O7,9(?53\+D)Y%O\`X4DS5;JBDJ8"+)&(
M/02B'%*L/R[Y,\%X/RUH-A/(=.S'#9`\B:KQIAN'7IT:V5IDE&PM/FI.(R^W
MD+&R?5"6C2W9JW7;MT9!1)TDN0P`"?<*E3SM\!^5U.T5;[!W$_DM=FH#[5@/
M1]&?<QKF.^P9CW$Z.V7R?<3]0_64/4.*55*'C3M@HG5-F.Q$=DNJ=T1CTK'(
M?CCDZME5L;C'SV/-$]0P.Q,BDDUJY/\`7Z.'!3O_`&O;3XI6`^+JGR2.D>TE
M%!N#>V_NMGNIR+3O-[C>?"E0T.DW4ZB4"&34["^G3T]?Z\ZQ^X+)L*Y8V]F"
MK5C?IV/>2KXM^=:R1\;B]<*_:GA92."]UX`)TYCZOEHZTWZA[VS;8!^%C8>E
M?)B2$!UIWXE7Z0E&%KVP&-5IH'ADR%!V\ALJ1+,1((@FH)+4[1!'^H@<2"'Z
MN5-R2O'R=R0PJ_NG\+*"-/P2N(M77N/T0K5^%_2O&TX8D<-\0RT6]BQN.&IS
M58#4MN>VGIZV?4G3^.D]ZDTRK#=:^WPTBU2]HWD7J4_:!?)@G\EDUP93U,=*
ME.9(#KMT;:,.+41'M^002E,/02C`G9ZTX>&&%'5^QWFVM)O91GO>Y'?H2SY]
M?KI-R/6MGL8MM>X,@9*!I/)4=U_4+:DIQ<8PS>UR!(]OH]-8L">U65\T/73U
M:ERGAFGYJCUZIDYLE<\6R]?E(*X8AL,17)B@W@SN6KDS$2MD:R4,ZF57]7>5
M[JR(W>MVHB[5,NDL<B!D5*VT`````!T`/0`#T``#^@`'%*<4J/6W&0[#B+5+
M9S+%1402MF,->LT9#K"KE,56R=AI6-[+9(51PD42F40))1B0G*`@(EZAQ2J?
M_P"V9PGCS'WB?P7F&!^#8LK;4/+WG'/>4%P1?6V_9%FLA6R-63L\^8[B0D%:
MJRCB,`255$J;DCA7L(LX7$RE7Q7&H5?(-2M%#NT%&VBFW6O3-4ME;F&Q'D3/
MUNPQ[B)FX:3:J?H<,).-=J(JD'T,0XAQ2N&B6J.\.M]]OW]K_B%]8"XUV6R`
M.0===JW4Z565PWXT+^O9[+L+3%TW"AGK^W5F2AI"NL0_05V>0>E`42.&0D4J
M=7FLP/BZCLO!-XH:FV:8_P!+,L[B4W'V1*4BZ7:M[=1\,HTH]=HU@>(*M0E0
MN\O;W"SU5;JLZFCHNQ$5B]14KJ[@H*$J\+$5NM0\77Z[`1K*&@H*$8-8N'AH
MB-;)LXZ+BHQBD@SCXY@T1(DBBD0B:290*4```#BE<X'ED_\`VI_MZ?\`FMMS
M_P!+*GQ2NE3BE<K]"KV)?*KY=O(;DO,4S5Y?5S3'`UF\9V)8J9F8-%C-Y1S!
M$R1MJ;O#(NEO<^U@6+M:NE=E,!#MUD#)_J3$04K;O@+V'N=3T>V1TLR.^);\
M^>*+)66-?7K=%VW>+W7&=;_(++@FQQRL>L_(M"3L$U7B(\4^XP-XI/J7J(=R
ME8M_:N4ROVCQ]6W<^RH?D&RNY&QF=L@Y\R7-&3?VR=E(3(DU7(:O+22A1>-(
M");QYWB+'J5--U(+J`4"G(!5*OVVD_\`C+L7_P`B<N_]/[#Q2N0#P4>0??'"
M7BTUAQIB'P][";/8[KK7)@5O-U,SEB&H5F[(R.7;W*/U(JOVE(TVP)#2KQQ'
MJ`KU`ZS4YR_I,'%*FCYBGSR3\O?]MS)2,6O!R$AG#-[Y]".ED7#J'>.XK"2[
MJ+<N&XBW77CUU#(G.F(D,8@B7T$.*5U2<4IQ2JT=46Q,.[?[IZ^O2E9Q]XL-
M>V@QPU,7VFTC`WYF$'?!8I'*/NC$VZ.317$#FZB<!Z!Z\WSR,L[GXRVKO1HZ
MGXC#F*DGN4N1U>2/J/IK945)Z>AZUS#Q(TG9G,F]^.GP&X\^2UG(:>P6U+3X
MI92#_P!N0A*%6)OT-AUK&L;XM>*X]V3TF0?)0MWP]D53,6OLI(=12"IVNX'R
M]AZ>;B;J9:.JV163V"D/9+VHIM13[0`Y`&_SNX6DYK!<KJ07<3DX(A9%">_F
M99]E-;/P4[&4B0WJZJ*[W-C6*VSM1Y>W-S\&(<#&=PV2.1Q"U]O;R))R..='
MQ0Q,2[%>TBR0V4V&H`[=2G8BYQ3O-*D5)15-R%`L:5L76VH"2WX8R?C9VJ6+
MNBS<B"KL7U!E@.RD5"D,8&B$;))E4:(',:,JB2<5(3M4.-N92$\I_&NG_HSH
MLH#6P"2!ID(LML$@:U/L*(<6`)BB?#S<1>]U,NM87(QTQ<RRG_R,;.A*/CDD
M`%6J(Y=IY0!(;1&DI"F4*)D[!W]W'QC4+HW4<D,V;JL+S5F+F>I]K9+`W*TE
MFIX1.1<0KA^"Y3&;+D]D!$10773#O"`2\,V\^HXI02=1"H[R@V\RH7U(/DTA
M838@*2=7\Z$*Z5M2!N%Z-%0,VDJ3I!1*80IV/(2;:7$^(++17<$H6-/_`&W'
M$BX]5?(C-TH=E586?M,J5Q\8R",3(P\6S/T(8R\G/S;-E&-6J9#]P^T9PN<`
M$$DE#`(<MT81UL!W(NLQX]KW*TK6?P2VVI2R?[0E(Z:E)'6KIS<C+JBQB6)$
MN6%:;!M;:$GIU6ZZE*$I`-_E*UGKI0HBU9G'2T7+D<J1<BPDB,GKB->GCWB#
MU-K),S`1XP74;G.5)XT.;M43-T.0WH8`'TYBWXTB,4ID(6V5H"DZDE)*5?E4
M`>Z2.H/8^E9N-,BS$J5$=;=2A90HH4%!*T_F02";*2>B@>H/0@&O1Y0JYKRI
MR$B+-"3%;L$<UEX&P14A"3<2^2*NRE(B5:+,)*.>(F_2LU>LW!TE"CZ&(80X
MI7,-@;4SRS>%YWD3#>C.)<7^17Q]S=TL.0<.8;NV:(S!>QFOBUKDPD)VCQ5O
MM[!>D6^K"[<'63!0WN.''>Y$&:BRY5E*N9T@S;O9FQ'(TSN;I96-,HUBI6"X
MHK3#8*IYXN%E2=!/FMCBY+4F+9UVL&BO9C2M$D7#H5Q67$Q@`A.JE0DRCJ'L
M18/[@C67=*'QXJ\UGH.B.1,/VW)86*J(HQ&19NUW>1C*X>LKSB5P=G=,Y=L<
M'"$>JT+[G0RI1*(`I4D/+%XW(CR6:XP^/(F_O<,YYP]D*O9PUES?&-SN7>,L
MR4[WCPC]\W0,F\=5R536,@](B<%DC`BZ3`ZK9,AE*A!4]LO[A7$T!$8TRKXJ
ML%[1WZ+CDHHVPF'-SL<XIQM<G;$PM`LUAH=]@PM=77ED4/D+HLVXI>\J/MMV
MR?1(BE:K\HV%?)5>MA?#7NKA?2V(S[E?4M#,-UV&PG3,YX[I5;K=WR30*)`J
MU2!R%D>3A#S<2SE@D@;/T&#CWDV)1432]XO%*EC1-T?+]DG'6S*5S\1LEKM?
M*MKO>K'KN\4VSP'E5/)&?16BX6B4!Q'14C#,X!@)Y=:6=2#]RDT*UBU$>HJK
M)%%2HQZ)?VV^@-=U)PBAO'JG2LR[?354-<]B\@6FW7>1FI+*MZDW]OM$2YD*
MU=&4"_)4W<U]21PT3]ER5E[W<H90RAU*]+!WBZM'C:\PE`RKH/KVA`>/C9G6
MN7Q/M/5JS;H@(C$F4J3*2EBQ]D0(*]7`;;/MI]46K`0CB/SM2NY!0Q2%.4AU
M*Q"@Z1^3;P_9=SHZ\:F.L1;J:)YZR-8<QI:A9#R@3!N4M?L@V0[8)MGB>^3S
M:1I4G3'Z*:2947?14R#-!,R*:Q%'CE2I_P"),O>2_:3'VS-4V7\?%6T_J,UK
M]D*`Q8S5V=H6:LD73)<_!.8AA"2;"DL6=4K$$HV?*B#I9^H/O%(`]I!,(*53
M7XQK[YQ_')I%AG3LOA&DLL#B)&YIA?B[PZV5$)_\LOEFNQ3&KQY:>-'F8_D7
MQA`'2H']GO\`3NZ`I4A_+M@;R)9EV'\,.[.NFD[K,5YU-?Y%RKG/`Z6;\3TU
M2F6N[0>'W"6/3WZV3L9%S)V<G$2;4)&-;/6YS,>\2E(JGU4JR;2_;SR7YNS&
MK2]L?%:]TYQ42GSDRGEYQM=AO,Q%;2P=Q*,/4@I]$#[LIIIL\<J_,'_10^+V
MF]3EXI5L?%*@IN3CRX13S'&U^(89Q.Y5US=R;N7JD<3K(90PK/II)Y+Q^W*4
MIA=3";%`).(*;N[7[;M(43JAS;O%^:Q<AJ=QSN9U+.W<XE"4/*_+$G-DF+)/
MP05'Q/$6NVJY-DUH7FG;F9B/XWEO9S*G]U[;6M3D=`^>=C70!-B`?Q.!`\T<
M&]G4$)!4L5[5NC6NP%7Q3M?J]8H1[D2M0SJ3HSU\N9G7\DT:>!%2V8;OJS<%
M7$4WDW;(GMJJ$46@9UHFL*8]BZ9[;&ON;,R&1XYY`8>1A'W0F0E(NY%D-W\,
MV.#8+*0HW`(3(CK*=75"A>9F*UR'BL3RYQ5)87N2*RI<52CI9FQ7;&1C99%R
MV%J2-*B"J)*;2O2;.)5\5-F665Y>8RS@B12QQFV/"/@\YX0R*V79)R,A'(_'
M;0^2H./,I(0=ECT$A2A;=&INT'C$I0`L@S!)-*KE(KNW8S6V]WH,[:B]3D"?
M&(44I4;E<5Q7RN-*)N_#=*%(<)-V7=150PLUG=TM[=VP'!C-]-Z&LIBYB2D+
M6@62W-:1=;3R`"F-D&0XEQH`6D,Z4H]!K,URI+.%I:JYGUXE`.I(2S.J0KZ]
M8N>OG"J?OO(]2LPMWI1"NEG'<)C,H=ZL/4RR(&+Z4'(L[)(2F-(Q6;CV"4*>
M6F/+2D`V2H.K8?Z`6L%O(3V0H@U<,S<9AW%+EQ,WMN5<K<2PTN5!4I1%U(+#
M4J,-1-[EJ.XKJ5H!%?,ZOE#LR"K=:\;!9E[%/CJU:DT.S0#&1!?W/;;2$C5J
M72(T&8F3$AS/)9!H(#T6'M$>5&\/F("PM,3"XNXN'7Y#3BDVM<I2Z^^K5UN`
MAE2_5'6J;NX-OY1!;7/W%F[&Q8C17VDKO>P6MB-%1IZ6/DD);]%]*V73G-XB
M$D;':HVF:_88IL5)*(411S`.Y99F"*HA,W:R-%25"E1<:4QG`,HU5X<ZH^XN
M_`O>@;`Y1O$R5&#CG)6:W3*<2#(`<"`JX^1AHCS/K5^7R.A``^5#-[+$GPKN
M>AI&3RS4+;NR83*R(I4RIPIL?U)+R2(\9M'5?B94X2KYG)%KMG<U-N-=R!68
MBXU)^:5K<\W,\AY,64A'DD&8+*H$>-V\FU9/!:.12$Z*HI@1=(2J)B9,Q3#%
MLIC)V&GNXO)(\<YE6E:-25:56!TDH*DW%[*%[I-TFQ!`FV%S6-W%BV<UAW"[
MC)"=3:]*T:TW("@%I2K2JUTJM92;*22D@G)N6%92G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*@-:<39.UFNUARYK'7@NV-+E*.;%F76)LY:1BS
MB==`)Y3)>#GCPZ4;#W)Z!`-(P2ID6$R<.],Z+D2B;<F/W)@-^XIC;6_G_:9Z
M*V&H65(*P&Q^2+/2FZEL)[-2`%.,#HH*;O;GS*[0W3Q?G).\.+8WOML375/9
M'!I4E!+JNKDW%J59#<E5KO15%+4D]4J0[:^50SK6O<3V+C3;%*UW+%-2-&N9
M>N/WV,]@,9*B<#.:W;H9=-"=;,2.#B!XV89O8=P<1,5-4!`XXZ4WOOC&^+RC
M#;^W)1U!#J4RL=*'HZRL7;*K=G65H>2+`J2>E96$]QCS/IS6$DO1MW0AH4XR
MM4++P3?YF9#9`=2C42"S(;<CK-R$K!O6<-:WM34P*UB\D8LRQ')@J*2F1:?+
MT2V'``(5NW>V&@.Y*MNC`!3&473K[;N$>@)!TZCB')_'>2/DD0<CC7S:XC/(
MD,_B4MR$I='X),E5OYO2L\UC.6<0/%%R>)R\87L9D=R+(]+!3T12V5>I*TQ$
M7)_*.Y_IR&W\J4K=`-<Z0!C`1:3*ODC([DB*@&*HLTBU6.-6Q'3?J!B`JX53
M4,'0P`'KPW_3*,=:_KDOX(M%C"_P*PJ4;'L;)!'H37ZZ.998\;?[:@@FQ7>;
M,(![E+93"`4.XU+4#Z@5C;G7ZME#\]V@RQ(Y>2K9R3(-KVI"47!]669F!5&5
M2QO'*MZPNJP-U%)W/N9APAZ"54IP[AOF]Z3B?H_'^-1C%/C1>.')$]X*Z%!E
M*!=`5ZHCI92KL4D=*QKO'>,`_<'*F7<S*(I#FF46HN+8*3<."$@A@E!_*Y+7
M)6GN%@]:_*E;*S&;KY"Q>OE*_)L-1,BJ6_9ZLY9&!HT@T:H+)_CV'&PMTI#(
M<RH]%,%)-,J<$U2(<`7<*&(0/65V)%VGAW9&])?M]T.('M\>UI<?220?)--R
MF,@)O9HDR%DCY$`$UYP?)TS?6?8B\=0?=;*9=/N\J_K:BK2D$>'')L%S'"JU
MWT@16TA5EN**14ON:SK<=.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI4#MK?X9??0_P"\?M?O5\?_`+E?M-^3_P`D.SM)['XW^U?_`(B?7]>G
M;\C_`(;_`%[_`$[N;@XZ_JE[-W]KW_:NK]?WGB^F?CY?=_Y;5_R_J_#K:N?^
M7/Z)?4&?WK;]\:?\M]/\_P!9MTMX?8?YS1\-?Z/\W2]1R:_SR]I?]A?Y&?BO
M8E]1_*G^.?V_^=7M]S_U"^#V].[[+_?NW_-^KIR<N?T>U#]X_0_J-SK^D_4]
M']W_`*VKX>+]/X=*UJS_`+@-*OZ?_N7Z38>/Z]]'\G<]_P#W-/Q\WZMN_6OR
MD_\`[9/C/?O/K_K_`(*G_E'^Q?Y3[O>'=\/]Q/\`A7R?:_[/_#K_`%]>G/3'
M^W'R(]IK\VL?^9[_`,5O\7MOGM?O7F5_N\\:_?>/VWC/_P"?]+\][_P^\_3O
M;M_QKX:W_%#\QA?YC_R._<+YZ/T/\X_F?M;]Q\M7V_Q3\9_]M_7Y/7V.[_4Z
M=O;Z].5I_P#4;Z8[_2_Z']%T'R?0=/N]%A_UO+_J?;\UNG>_K5OC/Z1_6F/Z
MT_N;]Q^0>+]T:O8>34;>W\'^C?F_)?YK6MZ5<)'?7?7L?J/A?5?$;_6_7>Q]
M?\#VB?$^#\;_`';XGL=OM^W^CLZ=OISF-_S^9?N=?N-1U:KZM5^NJ_6]^]^M
M^]=FQ?;>V;]GH]IH&C1;1HM\NG3\NFUK6Z6[=*^WE*J].*4XI3BE.*4XI3BE
5.*4XI3BE.*4XI3BE.*4XI3BE?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pg1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg1.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X00O:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C8M8S`Q-"`W.2XQ-38W.3<L(#(P,30O,#@O,C`M
M,#DZ-3,Z,#(@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z1#4W-38Q1#5$,C4X,3%%-#E$0C)%-3$X1#A$
M.3$T13@B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z1#4W-38Q1#1$,C4X
M,3%%-#E$0C)%-3$X1#A$.3$T13@B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#ID,C1C9#1D-2UE-&1A+30W,V4M8C8Y,RTU
M-S!F,V4S,&9E8C4B('-T4F5F.F1O8W5M96YT240](G5U:60Z9#@P93<R.3@M
M,S0S-2TT-F0W+6(R,3$M83`S9F%F,F,Y9#9C(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YG:6QA;'9A<F5Z/"]R9&8Z;&D^(#PO<F1F.E-E
M<3X@/"]D8SIC<F5A=&]R/B`\9&,Z=&ET;&4^(#QR9&8Z06QT/B`\<F1F.FQI
M('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@0UE#0R!0
M4B`T43$T($9I;F%N8VEA;"!297-U;'1S($9)3D%,+F1O8W@\+W)D9CIL:3X@
M/"]R9&8Z06QT/B`\+V1C.G1I=&QE/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R
M9&8Z4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0
M:&]T;W-H;W`@,RXP`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X0DE-
M!"4``````!#\X1^)R+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;`(0`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("
M`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`
M&`)-`P$1``(1`0,1`?_$`&X``0`#`0`"`P$````````````'"`D&`P0!`@4*
M`0$`````````````````````$```!@(`!@(!!0`"`P`````!`@,$!08`!Q$2
M5I;6&!,((3%!(A0543(C%A<1`0````````````````````#_V@`,`P$``A$#
M$0`_`/[^,!@,!@,!@,!@,!@,!@,!@,!@,"M_VZL]BIOUVV98ZG+O8*P1L2R-
M'2L<H"3UHHO,QS90S=42F^,YT%C%X@'$`-^.`_G`K7]:[O8Y/=4-`4>\7?8V
MKG6H(Z;V*\M;N2FXVL;*7!(_]2$GI5HBL"[HXB"C5-11,I1,(!_`.`:28#`Q
M3J.T-D348$O4]KWRQ?81S]@).!B=>#.+2<+*:UCI4"R"LM5CMC1L?!1[,%.=
M]Q3$@$X<>(?@-JR\W*7F``-P#F`!X@!N'Y`!_'$`'`^<#,7[#W60:?:^&ILY
M?MO5N@.M6H22T;JA677E33II.11;._\`/B(^37^`Q0X+J_$)2E*7F$`_.!I?
M'I%08,4"+.7!46;9(J[PPG=KE31(0%G1S%(8SE0`YCB(`(F$?Q@>W@9V?:^[
M6*J[?H2%YL^S:']?'=:>$=VO6"BS-9O?%7:J;0]ED6K1VX18,VX)F(ERB4X&
M$P%-_,`"_-<<,7=>@W49+&GHYQ$1JK&<47(Z4F&AV:)F\FHY3*0CA5\D(*F.
M``!C&$>`?I@?M8%"ON5;[A4I_5+A_*;!KFB5GDL&S['K$RB-C9/OB3+!)O'S
M=%=TQB"J&%0PD`/EY3`'$P%`0M[K1_!R=!J3^M6E[=H)Q",CQEKDG8/I*<:@
MGR%?2#H$6PJOCB405XID,50!`Q0$!#`[C`8#`8&8WV`OP,_LQ/U>Y[<N&O*#
M#Z23LD$E7+&Y@2#>57SI&/%)%FD<TN^><O`C4X'*L8@%`/V$+A?6B2V;+Z3H
MTAMY!TA>G#!<9$9!`C24<,RO7!8EY+-$R)D;2;J,!(ZQ.4H\P\1`#".!.^!2
M/[Z6^STO45=DJM8YVL.W6R:O&O9"NNEFDDI%NDY'^ZU2.@`J*"J0G$I``>8Y
M2_@1P)TT(:%5U\W<P$_LJR1KN6E%DY#:Z<DA;2JE5(W6;'0EH^,>I1R2B`B@
M`I<H@81*(@/'`FC`I[]Y[79J9]?Y:<J4]*5N92L]3;)RD.Z49/DV[J632<HD
M73X&!-=(>4P?N&!:R`547@H598YE5EHB-554./,=111FB<YSF'\B8YA$1'_G
M`_6P*B_>*TV6F_7BS3U2G9*N3;:7K*3>5B79V3U%-Q,MD5R$<)B!BD62,)3!
M^X#PP.O^LSB(?T!61B+-M2SE>2"0OG6UTY5&6;R)(N/%TA#I2\;&./\`#,<_
M.D<A3IG,8PE..!8O`CW;%Y:ZTUI>;Z[,4J=6K4K+)`;AP5>H-CA'MP`1#B9T
M_.FF`?J(FP*A_3*Z[&;SU^U/MVQR=CMK>%I>T(5Y+N%%W!8&[0S9P^C$#J\#
M`A#21RI<@?@AC&#`O]@,#-+2E^E'7V&L];WG?=GU3:Q;K/A2J0X>GCM666E_
M"NG"Q\0S*R,SD%01XN"*"H518Q"B!C&YR8&EN`P,N8JY/9O[A;4J%MV'NAG$
MP]QIR%(@*.M,.:RBZ<MF"KEI:"L8U^UC8)PH!><RYD$C`=3^?ZX&HV`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!$F]M8J[DU1<-:H
M3!(!6TLFS0DNHS%^1D+>0:/A.+0J[45N8&O+PYR\.;C^V!W52@2U>KUVN@JF
MX-!P<3$*.DT0;E=J1D>W8F=?"`F^,5Q0YN`B80X\.(_K@=#@,"@,-])W]:C*
MZ_KVQ48S8M1VY8MCP5O2KQ_A-!V=5$\K295@64*H^CG)4>`G%4`XF-P)_(<"
M_A.;E+S\O/RAS\G$"\W`.;E`1$0+Q_3C^>&!]L"I.Q_K[?Y_=[+=^O-E0U,G
M&-)"EIM)BGC9VYFRCITY<N!*:7CB<RGSE`H</X\GZCQ_`6M9D<I-&J;U<CIX
MFV0([<I)?UTW#DB12KKIH<Q_A(JJ`F`G,/*`\.(\,#V<"L>_],;,W*V=U6'V
MNQI^M[#$-HBV5M2EL9J3=@B_,\6>QDVN\169KN4P33$O+RD^,#`/$1P)VIE4
MC*+4JW387YO\FKPL=!QXN#_(X.VC6J;5-1<X`4#+*`GS&$``.81X``8'38$!
M;SUMM'94:$#1MGQM$K\M#RD%;8Y_3F5E4E64H":1W#%XX=MU8YV@U^1,H``E
M'Y./$!`,#N=3:VA]0ZZJNN(%PZ>1M6C08I/7O)_;>K*++.WCQ<J?_C3.Z>.#
MGY"_Q(`@4./#C@2)@,!@,"HNR_JE$[3V==+O8IU(\);]2_\`S;_!"+YW<7(H
MR`2<?:&DF+L"@ZCG9"'33!(H\2_]N`C@3IJ:J6>C:^K50M]I3NDS76!(HUE*
MQ4CEI-DT$4HX[QLH[>B+U%F!$U#_`"#\@DYA_(C@2-@5Z^R>D'F^J1$51A9D
M:JZB+="VM&27BS2R9E88'0I-C-"NV0B"BJY1$W/^A>'#\X$G:_B[W#P`M-B6
MN*N5A_ONE0F(>NEK#,(]0$OZC/\`S"OI`!6;B4_,K\G\^8/P'#`[?`@G[&Z:
M7WQK!]KQO/IUE5Y+PLH655CQDR)_Y#TKOX1:%<M!-\W+R\><.7_@<#L]90%[
MK5;+$[`MT3<I5NX^-E)P]<"L-T8E)NW0:,E&)7\B"RZ)DC"97G#GY@#E#A@2
M'@0;]BM/+;VU9+ZX0GDZVI*/HAX$JHP-)$1"+?HO3)BU*Y:"<5@2Y>/.'+QX
M_G`Z;5E;V#5H`\3L*YQ%U>-U4$8A[#U@*NDRB6S)NV29.&X2,C_<<`HD8XK"
M8HB!N'#\8$F8$([\U&ZW;26E#"PEK\,YL]?E+/P9'>*S,##/BOW4"D)'34&H
MR*J28"J//R`7_J(X$>P?U6KM%W74]K:T?DJ47&5N6K5IJ:A928+96S_B9HN2
M3D99PNP.P5*F)2<ITQ^(.`%_/$+88#`IZ/UMO-JV]3MD;8VNWN,5K28EIFA5
MV)IS"M+-G,BO\K8DU)MW;A1^E&D32*4`*`J_"41$O$W,%PL!@5!C?KULBK[O
MOVV:9M*$B8S9$S`O+)6Y&D_ZRYXJ&2;H&CV<H::;@U<.$RJ@"X)#R_('\1Y?
MR%OL!@,!@,!@,!@,!@,!@,!@,!@,!@0@M]B]1H++(*V&4*J@JHBJ4*7>#@51
M(YDS@!R5PQ#@!BCP$HB`_J`\,#Q^R&G^HI7LF]>-8#V0T_U%*]DWKQK`>R&G
M^HI7LF]>-8#V0T_U%*]DWKQK`>R&G^HI7LF]>-8#V0T_U%*]DWKQK`>R&G^H
MI7LF]>-8#V0T_P!12O9-Z\:P'LAI_J*5[)O7C6`]D-/]12O9-Z\:P'LAI_J*
M5[)O7C6`]D-/]12O9-Z\:P'LAI_J*5[)O7C6`]D-/]12O9-Z\:P'LAI_J*5[
M)O7C6`]D-/\`44KV3>O&L![(:?ZBE>R;UXU@/9#3_44KV3>O&L![(:?ZBE>R
M;UXU@/9#3_44KV3>O&L![(:?ZBE>R;UXU@/9#3_44KV3>O&L![(:?ZBE>R;U
MXU@/9#3_`%%*]DWKQK`>R&G^HI7LF]>-8#V0T_U%*]DWKQK`>R&G^HI7LF]>
M-8#V0T_U%*]DWKQK`>R&G^HI7LF]>-8#V0T_U%*]DWKQK`>R&G^HI7LF]>-8
M#V0T_P!12O9-Z\:P'LAI_J*5[)O7C6`]D-/]12O9-Z\:P'LAI_J*5[)O7C6`
M]D-/]12O9-Z\:P'LAI_J*5[)O7C6`]D-/]12O9-Z\:P'LAI_J*5[)O7C6`]D
M-/\`44KV3>O&L![(:?ZBE>R;UXU@/9#3_44KV3>O&L![(:?ZBE>R;UXU@/9#
M3_44KV3>O&L![(:?ZBE>R;UXU@/9#3_44KV3>O&L![(:?ZBE>R;UXU@/9#3_
M`%%*]DWKQK`>R&G^HI7LF]>-8#V0T_U%*]DWKQK`>R&G^HI7LF]>-8#V0T_U
M%*]DWKQK`>R&G^HI7LF]>-8#V0T_U%*]DWKQK`>R&G^HI7LF]>-8#V0T_P!1
M2O9-Z\:P'LAI_J*5[)O7C6`]D-/]12O9-Z\:P'LAI_J*5[)O7C6`]D-/]12O
M9-Z\:P'LAI_J*5[)O7C6`]D-/]12O9-Z\:P'LAI_J*5[)O7C6`]D-/\`44KV
M3>O&L![(:?ZBE>R;UXU@/9#3_44KV3>O&L![(:?ZBE>R;UXU@/9#3_44KV3>
MO&L![(:?ZBE>R;UXU@/9#3_44KV3>O&L![(:?ZBE>R;UXU@/9#3_`%%*]DWK
MQK`\Y?L1J4[9=X6P2@MVR[5LL?\`],NX"59ZF\5;E!,:Z"IP.1@J(F*42EY0
(`P@)B\0__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
